Pfizer has announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has approved a new presentation of Prevenar 13 (pneumococcal polysaccharide conjugate vaccine [13-valent, absorbed]). Read More »

One pharmaceutical company executive stated that the challenges retail and outpatient pharmacies face in regards to the reimbursement and regulatory environment can be solved by technology. Read More »

The Children’s Miracle Network Hospitals has announced that it will be entering a collaborative effort with the United Networks of America (UNA). Read More »

CVS Health has announced that its specialty pharmacy, CVS Specialty, has been awarded Specialty Pharmacy accreditation from URAC. Read More »

GlaxoSmithKline (GSK) has announced the approval of Nucala (mepolizumab) by the Japanese Ministry of Health Labor and Welfare (MHLW). Read More »

Rich Pharmaceuticals Inc. announced this week that CMIC ASIA-PACIFIC PTD. LTD., an Asian contract research organization (CRO), will run the first phase of an upcoming oncology clinical. Read More »

The APhA (American Pharmacists Association) House of Delegates has published the report detailing the polices that were adopted at the APhA Annual Meeting and Exposition (APhA 2016) in Baltimore, Maryland. Read More »

The American Society of Health-System Pharmacists’ (ASHP) Midyear Clinical Meeting and Exhibition was recently honored with three awards. Read More »

Blue Cross and Blue Shield of Illinois (BCBSIL) and Illinois Cancer Specialists (ICS) have announced the very first oncology intensive medical home (IMH) pilot program in Illinois. Read More »

Amgen and UCB have announced the results of the Phase 3 trial for romosozumab. Read More »

In the wake of recent scandals involving drug manufacturers such as Valeant, renewed attention has been drawn to the skyrocketing cost of prescription drugs and the attendant problem of rising health insurance costs across the U.S. Read More »

The U.S. Food and Drug Administration (FDA) has granted orphan drug designation for Iomab-B, a radioimmunotherapeutic developed by Actinium Pharmaceuticals that is designed to aid patients with reverted and stubborn Acute Myeloid Leukemia (AML) so they can receive a Hematopoietic Stem Cell Transplant (HSCT). Read More »

Oasmia Pharmaceuticals, which develops innovative drugs within human and veterinary oncology, has announced that the first patient to take part in the Phase 1 clinical trial for Docecal, the company’s groundbreaking cancer treatment, has been enrolled. Read More »

Actinium Pharmaceuticals has announced that it has named Jennifer Liberi Director of Clinical Operations. Read More »

Recent research conducted by ResearchersAgainstAlzheimer’s (RA2), an UsAgainstAlzheimer’s (UsA2) network, reports 17 new drugs aimed at treating Alzheimer’s will be developed in the next five years. Read More »

Eisai Co. Ltd. and Ajinomoto Co. Inc. have announced the establishment of EA Pharma Co. Ltd., based on the integration agreement signed by both companies on October 15 of last year. Read More »

Eisai Co. Ltd. has announced that Eisai Inc., the company’s subsidiary located in the United States, has entered into a shared purchase agreement that will transfer all of Eisai Inc.’s shares of AkaRx Inc. to PBM Capital Group LLC. Read More »

Pfizer and Bristol-Myers Squibb have released the 17 abstracts that the two companies will present at the American College of Cardiology’s 65th Annual Scientific Session (ACC.16) in Chicago on April 2-4. Read More »

Sanofi and Regeneron Pharmaceuticals will be presenting new joint Phase 3 data from the clinical trial for the Praluent (alirocumab) Injection at the American College of Cardiology’s 65th Annual Scientific Session & Expo (ACC.16) in Chicago on April 2-4. Read More »

Teva Pharmaceutical Industries has announced that the U.S. Food and Drug Administration (FDA) has approved its interleukin 5 antagonist monoclonal antibody (lgG4 kappa), CINQAIR (reslizumab) Injection. Read More »